购物车
您的购物车当前为空
KRAS-IN-5 (Compound Ex 6) 是一种口服活性且选择性的抑制剂,靶向 KRAS 突变体(包括 KRASG12D、KRASG12V、KRASWT),对 KRASG12D 的 GNEIC50 值为 1.3 nM。它通过抑制 KRAS 介导的信号通路(例如降低 ERK 磷酸化)来阻止肿瘤细胞增殖。KRAS-IN-5 有望用于研究与 KRAS 突变相关的癌症,如胰腺癌、结直肠癌和肺癌。

KRAS-IN-5 (Compound Ex 6) 是一种口服活性且选择性的抑制剂,靶向 KRAS 突变体(包括 KRASG12D、KRASG12V、KRASWT),对 KRASG12D 的 GNEIC50 值为 1.3 nM。它通过抑制 KRAS 介导的信号通路(例如降低 ERK 磷酸化)来阻止肿瘤细胞增殖。KRAS-IN-5 有望用于研究与 KRAS 突变相关的癌症,如胰腺癌、结直肠癌和肺癌。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | 待询 | 10-14周 | |
| 50 mg | 待询 | 10-14周 |
| 产品描述 | KRAS-IN-5 (Compound Ex 6) is an orally active, selective inhibitor that targets KRAS mutants, including KRASG12D, KRASG12V, and KRASWT, with an impressive GNE IC50 value of 1.3 nM for KRASG12D. By inhibiting KRAS-mediated signaling pathways, such as reducing ERK phosphorylation, KRAS-IN-5 effectively prevents tumor cell proliferation. This compound holds potential for research into cancers associated with KRAS mutations, such as pancreatic cancer, colorectal cancer, and lung cancer. |
| 分子量 | 659.70 |
| 分子式 | C35H36F3N7O3 |
| CAS No. | 3082412-00-5 |
| Smiles | C(C)C1=C2C(=C3C(=CC2=CC=C1F)NN=C3C)C4=C(F)C=5C=6C(=N4)OC[C@]7(N(C6N=C(OC[C@@]89N(C[C@H](F)C8)CCC9)N5)CCCOC7)[H] |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多